Premium
Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach–Merritt phenomenon using four‐drug regimen
Author(s) -
Hauer Julia,
Graubner Ulrike,
Konstantopoulos Nikos,
Schmidt Susanne,
Pfluger Thomas,
Schmid Irene
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20750
Subject(s) - medicine , vincristine , consumptive coagulopathy , kasabach–merritt syndrome , hemangioendothelioma , cyclophosphamide , sarcoma , regimen , prednisolone , methotrexate , coagulopathy , surgery , chemotherapy , pathology
We report a case of a 6‐month‐old girl suffering from a kaposiform hemangioendothelioma of the chest wall, associated with Kasabach–Merritt phenomenon. Despite rapid intervention with cortisone and interferon alpha the tumor led to a life‐threatening clinical condition with progressive growth and consumption coagulopathy under therapy. Because therapy for kaposiform hemangioendotheliomas with a single anti‐angiogenic or anti‐proliferative agent has not been reported to be very successful, we administered vincristine, combined with cyclophosphamide, actinomycin D, and methotrexate in a critically ill patient. After six cycles of the applied four‐drug regiment, the infant was in remission, which has been maintained for 5 months since stopping therapy. Pediatr Blood Cancer 2007;49:852–854. © 2006 Wiley‐Liss, Inc.